Fda Drug

• Researchers analyzed the impact of the 21st Century Cures Act, which allows the FDA to approve novel drugs based on a single pivotal trial rather than multiple studies. • Findings indicate that since 2016, the number of studies supporting new drug approvals in the US has steadily decreased. • This shift reflects a trend toward increased FDA flexibility and a higher reliance on industry-funded data to accelerate the drug approval process.

• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer. • The approval is significant as it provides patients with a new targeted option for managing a disease known for its high mortality rate and limited treatment efficacy.

• A new analysis reveals that more than two-thirds of new drugs approved by the FDA in 2024 were sanctioned based on the findings of a single study. • The report indicates a steady decline in the number of studies required for drug approval since 2016, raising concerns about the rigor of the process. • Researchers argue that this trend necessitates stronger post-market surveillance and more comprehensive trial reporting to maintain the integrity of drug approvals.

• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease. • This approval is significant because it provides patients with a more effective treatment option for one of the deadliest types of cancer, which often has limited therapeutic alternatives.

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancerThe US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that has eluded drugmakers for decades. Continue reading...

• The FDA has granted approval for a new narcolepsy medication developed by Takeda Pharmaceutical. • In a significant medical milestone, the first-ever mRNA-based influenza vaccine has also received FDA approval. • These approvals highlight the expanding utility of mRNA technology beyond COVID-19 and provide new treatment options for sleep disorders.

• The FDA has approved Replimune’s treatment for advanced melanoma, marking a significant victory for the company and patient advocates. • The drug's approval follows a tumultuous process in which it was previously rejected by the agency twice before clearing an advisory committee last week. • This decision provides a critical new therapeutic option for patients suffering from advanced stages of skin cancer.

• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.

• The FDA has raised concerns regarding the efficacy of Capricor Therapeutics' treatment for Duchenne muscular dystrophy ahead of an upcoming advisory committee hearing. • The agency's skepticism contradicts claims made by Capricor regarding the clinical benefits of the rare disease drug. • This development is critical as it may influence the FDA's final decision on whether to grant regulatory approval for the therapy.

• An FDA advisory committee is meeting this week to review applications for novel peptide therapies that were previously rejected by former agency officials. • Affiliates of the American Academy of Peptide Medicine allege the FDA ignored critical safety and efficacy data, while industry and consumer advocates warn that approval would bypass traditional drug regulations. • Separately, the FDA’s oncology center released three final guidance documents on Monday designed to expand patient access to cancer clinical trials.

• The FDA has introduced a new fast-track program for the approval of biologics, which are complex drugs used to treat conditions such as cancer and sickle cell disease. • Traditionally, the agency requires a rigorous process involving an investigational new drug application followed by three distinct phases of human clinical trials. • Experts warn that these political shortcuts could undermine the FDA's international reputation and its standing as a global authority on drug safety.

Move comes as prediction platforms rapidly gain popularity and offer opportunities to bet on virtually anythingKalshi is expanding its wagers to include bets on drug trial results, an expansion into new predictions territory as platforms continue to rapidly gain popularity and offer opportunities to bet on virtually anything.The betting platform said the expansion into clinical trials and FDA regulatory decisions would help surface information on drug trials that otherwise go unreported. A publicly listed contract on a drug trial would produce a “continuously updated, public probability that reflects the weight of the evidence, rather than the preferred message of the trial sponsor”, the company said. Continue reading...

• The FDA has introduced a new fast-track program for the approval of biologics, including experimental gene therapies for conditions like sickle cell disease and cancer. • Traditionally, the agency requires a rigorous three-phase trial process involving healthy volunteers, dose-finding studies, and large-scale clinical trials to ensure safety. • Critics argue that these political shortcuts may undermine the FDA's international reputation and its standing as a global authority on drug safety.

• Leading researchers are warning that a recent FDA policy shift may lead to the approval of ineffective medicines. • In February, the FDA announced that drug sponsors could seek approval based on a single clinical trial and confirmatory evidence, departing from a 1960s-era requirement for two clinical studies. • This change is concerning to experts because it may allow drugs with conflicting trial data to enter the market, potentially compromising patient safety and efficacy.

• The US Food and Drug Administration (FDA) approved 22 novel drugs during the first half of 2026, expanding treatment options across various medical specialties. • Key approvals include copper histidinate (formerly CUTX-101) for Menkes disease, supported by two open-label studies involving 129 patients treated with subcutaneous administration for up to 3 years. • The FDA also granted approval for a new treatment targeting mild to moderate Alzheimer's disease (AD) based on phase 3 clinical trial data from both adult and pediatric populations.

• On June 22, the FDA announced several initiatives to accelerate both early- and late-stage drug development as part of the Department of Health and Human Services' "Operation TrailBlazer." • A key component is a new drug pilot program designed to shorten the timeline between initial drug identification and first-in-human clinical studies. • The program aims to establish a network of qualified research institutions, including academic medical centers and contract research organizations, to collaborate with sponsors on protocol development.

• The FDA has launched a new initiative aimed at resetting the drug review process to accelerate the development of new medications. • A primary goal of the program is to boost the number of domestic clinical trials, reducing reliance on overseas data and speeding up patient access to therapies. • This shift matters as the agency seeks to streamline regulatory hurdles and improve the efficiency of bringing innovative treatments to the U.S. market.

• In early 2026, the FDA implemented four strategic actions to modernize drug development, shifting focus toward flexibility and human-centric science. • The agency is prioritizing evidence quality and analytical sophistication over the sheer volume of data, acknowledging that advances in genomic medicine and biomarkers have outpaced old frameworks. • A key regulatory change allows for drug approval based on a single adequate and well-controlled trial, provided it is supported by sufficient confirmatory evidence.

• The FDA has fast-tracked bepirovirsen, a first-of-its-kind drug for hepatitis B, following trial results showing it may allow some patients to stop treatment entirely. • In a study of 1,838 patients receiving weekly shots for six months, approximately 20% of bepirovirsen recipients achieved a "functional cure," meaning the virus remained undetectable for six months after all medication ceased. • This is significant because current hepatitis B treatments typically require lifelong daily medication to manage the virus and prevent liver failure.

• The FDA approved Icotyde (icotrokinra), developed by Johnson & Johnson Innovative Medicine, on March 17, 2026. • The drug is an interleukin-23 (IL-23) receptor antagonist specifically indicated for patients with moderate-to-severe plaque psoriasis. • This approval provides a new therapeutic option for managing a chronic inflammatory skin condition by targeting specific immune responses.

Dr Tracy Beth Høeg, the Food and Drug Administration’s top drug regulator, says she was fired from agency after declining to resignIn a major shake-up at the US Food and Drug Administration (FDA), top regulators left on Friday – including Tracy Beth Høeg, the acting drug chief, who says she was fired, and Katherine Szarama, the acting vaccines chief who has only been in the position for days. Jim Traficant, the chief of staff, has also been ousted.The FDA now has no permanent commissioner or deputy commissioner and no permanent leaders of two major centers, after the resignation of Marty Makary on Tuesday and other high-profile departures. Continue reading...

• The FDA announced the first ibogaine investigational new drug application as part of Trump's mental health executive order accelerating psychedelic drug approvals and research pathways. • HHS will coordinate with the FDA and DEA to expedite research approval and clinical trial access for emerging mental health treatments under strict medical supervision and scientific oversight. • The initiative specifically targets treatment-resistant conditions and addresses mental health needs among veterans and patients who have not responded to conventional therapies.

• FDA announced on April 1, 2026, that new drug approvals last year reached near-record levels, surpassing five-, ten-, and multi-year averages. • This update highlights continued acceleration in innovative therapies reaching US patients, boosting treatment options for various diseases. • Strong approval momentum underscores FDA's commitment to expediting safe, effective drugs amid public health priorities like cancer and rare diseases.